GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
MWN-AI** Summary
GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company specializing in cutting-edge therapeutics based on its proprietary TriKE® (tri-specific killer engager) platform, recently announced its participation in the 10th Anniversary of the Innate Killer Summit held in San Diego, CA, from March 3-5, 2025. Dr. Jeffrey Miller, MD, Deputy Director of the Masonic Cancer Center and Co-Leader of the Immunology Program at the University of Minnesota Medical School, will represent the company as a featured speaker on March 4, 2025.
Dr. Miller’s presentation will focus on the advantages of TriKE® technology, highlighting how tri-specific engagers enhance the activity of natural killer (NK) cells, improve cytotoxicity, and increase cytokine release. His talk will incorporate preclinical and clinical data associated with the technology, particularly emphasizing its potential in advancing cancer treatment.
GT Biopharma is actively evaluating GTB-3650, a second-generation TriKE®, in a Phase 1 dose escalation study targeting patients with hematological malignancies. The study includes approximately 14 patients suffering from relapsed or refractory CD33 expressing hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The company is on track to share initial data from this pivotal study in 2025.
As a clinical stage biopharmaceutical company, GT Biopharma is committed to enhancing the immune response to cancer through innovative therapies. Their exclusive license agreement with the University of Minnesota aims to further the development and commercialization of TriKE® technology. For more details, stakeholders are encouraged to visit their website or clinicaltrials.gov, referencing the trial identifier NCT06594445.
This engagement at the summit underscores GT Biopharma's efforts to advance scientific knowledge and showcase its commitment to transforming cancer treatment through immunotherapy.
MWN-AI** Analysis
GT Biopharma, Inc. (NASDAQ: GTBP) is strategically positioned in the growing field of immuno-oncology, particularly with its proprietary TriKE® platform enhancing natural killer (NK) cell response against cancers. The recent announcement of Dr. Jeffrey Miller's participation as an expert speaker at the 10th Anniversary of the Innate Killer Summit underscores the company's commitment to advancing its innovative therapy, specifically the GTB-3650, which is currently undergoing Phase 1 trials for treating hematological malignancies.
Investors should view this conference participation as a positive indicator of GT Biopharma's scientific credibility and potential market impact. Dr. Miller's expertise and focus on the efficiencies of TriKE® technology will likely attract attention from researchers, investors, and potential partners, enhancing the company’s visibility in the competitive landscape.
The ongoing Phase 1 trial is crucial not only for validating GTB-3650's safety and efficacy but also for generating crucial data that could attract further investment and partnerships. With enrollment progressing as expected, initial results anticipated in 2025 could drive stock momentum if promising clinical outcomes are reported.
However, potential investors should remain cautious and consider the inherent risks associated with clinical-stage biotechnology companies, such as regulatory hurdles, the possibility of adverse trial outcomes, and competition in the rapidly evolving immunotherapy sector. Moreover, with GT Biopharma’s reliance on its collaboration with the University of Minnesota for continuing development and commercialization rights, investors must monitor this relationship closely.
In conclusion, while GT Biopharma presents an intriguing investment opportunity thanks to its innovative approaches and recent developments, investors should conduct thorough research and consider both the potential and the inherent risks before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD 1 from the University of Minnesota Medical School 2 will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San Diego, CA.
10th Anniversary of the Innate Killer Summit
| Title: | Showcasing Advantages of Tri-Specific Killer Engagers to Turbocharge NK Recruitment & Potency |
| Date: | Tuesday, March 4, 2025 |
| Time: | 1:30 pm PT |
| Participant: | Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program at the University of Minnesota Medical School & Consulting Senior Medical Director, GT Biopharma |
Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and increase cytokine release, and the preclinical and clinical data shown to date.
GTB-3650, GT Biopharma’s wholly owned second-generation TriKE, is currently being evaluated in a Phase 1 dose escalation study in patients with hematological malignancies. Enrollment is proceeding as expected, marking consistent advancement in the trial which will evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The company anticipates sharing initial data from the study in 2025. More details can be found on clinicaltrials.gov with the identifier: NCT06594445 .
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE ® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
1 Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.
2 The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of GTB-3650 be realized. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
FAQ**
How does GT Biopharma Inc. GTBP plan to leverage the data from the ongoing Phase 1 study of GTB-3650 to enhance investor confidence and attract potential partnerships?
What are the key differentiators of GT Biopharma Inc. GTBP's TriKE platform compared to other immunotherapy approaches currently in development?
Can you share insights into how Dr. Jeffrey Miller's expertise will shape the future research and development strategies for GT Biopharma Inc. GTBP’s pipeline?
What potential market impact does GT Biopharma Inc. GTBP foresee upon the successful commercialization of GTB-3650 for hematological malignancies?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
-7.18% G/L:
$0.4084 Last:
1,935,580 Volume:
$0.4508 Open:
